Pharmaceuticals, Biotechnology and Life Sciences
Moderna, Inc. (NASDAQ:MRNA) has announced positive interim data from the Phase 2/3 KidCOVE study of the Moderna COVID-19 vaccine (mRNA-1273) in children 6 months to under 2 years and 2 years to under 6 years of age.
Moderna, Inc. (NASDAQ:MRNA) is expanding its mRNA pipeline with two new development programs. This announcement reflects the company’s commitment to expanding its portfolio by building on Moderna’s experience with Spikevax, its COVID-19 vaccine.
Moderna has submitted a request to the U.S. Food and Drug Administration (FDA) for an amendment to the emergency use authorization (EUA) to allow for a fourth dose of its COVID-19 vaccine (mRNA-1273) in adults 18 years of age and older who have received an initial booster of any of the authorized or approved COVID-19 vaccines.
Moderna today announced the first positive interim data from the Phase 1 study of the Company’s quadrivalent seasonal flu vaccine candidate, mRNA-1010, as it successfully boosted hemagglutination inhibition (HAI) assay geometric mean titers against all strains 29 days after vaccination at all doses tested in both younger and older adults.
Japan has suspended more than 1.5 milion doses of Moderna vaccine after getting contamination reports
Initial up-front endowment of $50 million Foundation to support charitable organizations and causes that promote public health, healthcare and educational…
-Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Tabuk Pharmaceutical Manufacturing Company (a fully owned subsidiary of Astra Industrial Group), a leading Saudi pharmaceuticals company, today announced an agreement to commercialize the Moderna COVID-19 Vaccine and future variant-specific booster candidates in Saudi Arabia.
After the US president’s Biden said the US Federal government would buy 100 million doses of the COVID-19 vaccine from Moderna and another 100 million from Pfizer, Moderna today confirmed that it is in discussion with the U.S. government to purchase an additional 100 million doses of the Moderna COVID-19 Vaccine for delivery in the third quarter of 2021.
Reuters news agency referred to the Economic Times as saying Monday that Tata Group’s healthcare venture has reportedly started the first discussions with Moderna Inc for a partnership to launch its COVID-19 vaccine in India.
U.S. FDA has authorized mRNA vaccine against COVID-19 for emergency use as total of 200 million doses ordered by the U.S government to date, with an option to purchase up to an additional 300 million doses, while approximately 20 million doses will be delivered by the end of December 2020.